Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting A3 and A2A adenosine receptors in the fight against cancer
Stefania Merighi, Enrica Battistello, Luca Giacomelli, et al.
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 8, pp. 669-678
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Adenosine A2A receptor antagonists: from caffeine to selective non‐xanthines
Kenneth A. Jacobson, Zhan‐Guo Gao, Pierre Matricon, et al.
British Journal of Pharmacology (2020) Vol. 179, Iss. 14, pp. 3496-3511
Open Access | Times Cited: 69
Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
Fabrizio Vincenzi, Silvia Pasquini, Pier Andrea Borea, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8710-8710
Open Access | Times Cited: 59
Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Fazhi Yu, Chenyu Zhu, Qiong Xie, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12196-12212
Closed Access | Times Cited: 56
Adenosine receptor antagonists: Recent advances and therapeutic perspective
Anjali Saini, Rajiv Patel, Sobhi Gaba, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113907-113907
Closed Access | Times Cited: 49
Pharmacology of Adenosine Receptors: Recent Advancements
Fabrizio Vincenzi, Silvia Pasquini, Chiara Contri, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1387-1387
Open Access | Times Cited: 16
Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Yasser Tabana, Tae Chul Moon, Arno G. Siraki, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 5, pp. 347-363
Closed Access | Times Cited: 35
Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
Rafael Franco, Rafael Rivas‐Santisteban, Gemma Navarro, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2831-2831
Open Access | Times Cited: 33
Buffering Adaptive Immunity by Hydrogen Sulfide
Giulia Pozzi, Giuliana Gobbi, Elena Masselli, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 325-325
Open Access | Times Cited: 21
Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer
Zhao Zhang, Yongbo Yu, Pengfei Zhang, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 21
Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System
Elisabetta Coppi, Federica Cherchi, Martina Venturini, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1890-1890
Open Access | Times Cited: 15
Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Fazhi Yu, Chenyu Zhu, Shuyin Ze, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 4367-4386
Closed Access | Times Cited: 14
A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma
Soumaya Rafii, Amina Ghouzlani, Oumayma Naji, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6688-6688
Open Access | Times Cited: 8
AI-based identification of therapeutic agents targeting GPCRs: introducing ligand type classifiers and systems biology
Jonas Goßen, Rui Ribeiro, Dirk Bier, et al.
Chemical Science (2023) Vol. 14, Iss. 32, pp. 8651-8661
Open Access | Times Cited: 8
A2aR inhibits fibrosis and the EMT process in silicosis by regulating Wnt/β-catenin pathway
Yangyang Tian, Jiarui Xia, Guo Yang, et al.
Ecotoxicology and Environmental Safety (2022) Vol. 249, pp. 114410-114410
Open Access | Times Cited: 13
ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3β/β-catenin signaling
Suming Pan, Sixian Liang, Xianyan Wang
Life Sciences (2021) Vol. 278, pp. 119581-119581
Closed Access | Times Cited: 16
Anti-cancer activities of cytokinin ribosides
Jiří Voller, Tibor Béreš, Marek Zatloukal, et al.
Phytochemistry Reviews (2019) Vol. 18, Iss. 4, pp. 1101-1113
Closed Access | Times Cited: 18
Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents
Flavia Varano, Daniela Catarzi, Fabrizio Vincenzi, et al.
Bioorganic & Medicinal Chemistry Letters (2020) Vol. 30, Iss. 9, pp. 127067-127067
Open Access | Times Cited: 15
Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A2A Receptor Inverse Agonists
Flavia Varano, Daniela Catarzi, Erica Vigiani, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 8, pp. 161-161
Open Access | Times Cited: 15
Discovery of Novel Benzo[4,5]imidazo[1,2-a]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A2A Adenosine Receptor Antagonists
Shuhao Liu, Wen Ding, Wei-Feng Huang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8933-8947
Closed Access | Times Cited: 9
Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist
G. Lakshma Reddy, R.J. Sarma, Shuhao Liu, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 113040-113040
Closed Access | Times Cited: 14
Combinatorial delivery of CPI444 and vatalanib loaded on PEGylated graphene oxide as an effective nanoformulation to target glioblastoma multiforme: In vitro evaluation
Vishnu S. Mishra, Sachin Patil, Puli Chandramouli Reddy, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Benzothiazole derivatives in the design of antitumor agents
Niccolò Paoletti, Claudiu T. Supuran
Archiv der Pharmazie (2024) Vol. 357, Iss. 9
Closed Access | Times Cited: 1
Differential HIF2α Protein Expression in Human Carotid Body and Adrenal Medulla under Physiologic and Tumorigenic Conditions
Lucía Celada, Tamara Cubiella, Jaime San‐Juan‐Guardado, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2986-2986
Open Access | Times Cited: 7
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents
Costanza Ceni, Daniela Catarzi, Flavia Varano, et al.
European Journal of Medicinal Chemistry (2020) Vol. 201, pp. 112478-112478
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top